PENAO / Beroni Group - LARVOL DELTA

Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma. (PubMed, Int J Cancer) - "Inhibiting this transporter with PENAO reduced cell viability in a panel of neuroblastoma cell lines in a TP53-status-dependant manner. We identified the histone deacetylase inhibitor, suberanilohydroxamic acid (SAHA), as the most effective drug in clinical use against mutant TP53 neuroblastoma cells...SAHA and PENAO synergistically reduced cell viability, and induced apoptosis, in neuroblastoma cells independent of TP53-status. The SAHA and PENAO drug combination significantly delayed tumour progression in pre-clinical neuroblastoma mouse models, suggesting that these clinically advanced inhibitors may be effective in treating the disease."

Combination therapy • Journal • CNS Tumor • Neuroblastoma • Oncology • Solid Tumor

Post-functionalization of drug-loaded nanoparticles prepared by polymerization-induced self-assembly (PISA) with mitochondria targeting ligands. (PubMed, Beilstein J Org Chem) - "Herein, the postfunctionalization of different non-fouling PISA particles, prepared from either poly(oligo ethylene glycol methyl ether methacrylate) (pPEGMA) and the anticancer drug PENAO (4-(N-(S-penicillaminylacetyl)amino)phenylarsenonous acid) or zwitterionic 2-methacryloyloxyethyl phosphorylcholine (MPC) and PENAO were reported...When TPP was conjugated to the pMPC PISA particles more cellular uptake as well as better spheroid penetration were observed, while TPP on PEG-based PISA had only little effect. It was hypothesized that TPP on the micelle surface may not be accessible enough to allow mitochondria targeting, but more structural investigations are required to elucidate this."

Journal • Oncology • Sarcoma • Solid Tumor

Beroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAO (GlobeNewswire) - P1, N=NA; “Beroni Group…announced that PENAO Pty Ltd,...has signed a drug manufacture contract with Aurigene Pharmaceutical Services, India, a subsidiary of Dr Reddy’s Laboratories Limited...PENAO, was shown to be safe and well-tolerated in a phase I clinical trial conducted in Australia where encouraging efficacy data was observed. In a second clinical trial to commence H1 2022, PENAO is planned to be administered as twice-weekly injections to patients with advanced solid tumors."

Licensing / partnership • New trial • P1 data • Oncology • Solid Tumor

Beroni Acquires Majority Interest in PENAO, an Anti-Cancer Drug Development Company (GlobeNewswire) - "Beroni Group...announces that it has completed its majority acquisition of the Sydney-based anti-cancer drug development company, PENAO Pty Ltd. As a result of this acquisition, Beroni now owns 60% of PENAO Pty Ltd’s shares....A larger Phase I/II clinical trial will be conducted in China and Australia to demonstrate PENAO’s efficacy in patients with advanced solid tumours as a stand-alone therapy and in combination with the established treatment rapamycin."

M&A • Oncology • Solid Tumor